Form 4: Cytek Biosciences SVP, Global Sales and Services, Philippe Busque, Reports Stock Transactions
SEC Form 4
Philippe Busque, SVP at Cytek Biosciences, reports the vesting and disposal of restricted stock units to cover tax obligations.
Summary
- On May 20, 2024, Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, engaged in transactions involving Cytek's common stock.
- Busque acquired 6,659 shares and 1,473 shares through the vesting of Restricted Stock Units (RSUs).
- He also disposed of 9,994 shares and 574 shares to cover tax withholding obligations at a price of $5.96 per share.
- Following these transactions, Busque directly owns 8,299 shares of Cytek Biosciences common stock and holds 33,887 Restricted Stock Units.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of stock transactions (vesting of RSUs and disposal for tax obligations). |
| 05/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.